CTHRC1 and idiopathic pulmonary fibrosis: Importantly, CTHRC1 has been reported as being involved in the mechanism of action (MoA) of pirfenidone, an anti-fibrotic agent approved for treatment of idiopathic pulmonary fibrosis and an ongoing study showing promising results for heart conditions (124, 125).